… ratio for medical therapy during pregnancy and conception in patients with IBD is a complex
… This paper presents the current evidence on efficacy and safety of biological therapy during …

… and immunogenicity of biological therapy. The safety profile in randomized controlled studies
of all biological agents in Crohn's disease (CD) and ulcerative colitis has been generally …

… We are grateful to Nicole Eichinger and Sonja Rosensweig, secretariat of the European
Crohn's and Colitis Organisation, for their help with the logistics of the meetings and to Christine …

… As a result, TNF-α has been an attractive target for biological agents. Three anti-TNF agents
… to anti-TNF therapy. Failure to respond to biological therapy is categorized into two types: …

… Areas covered: Our aim is to review the relevant data available in the literature and briefly
summarize the safety profile of biological therapy in UC. We performed a literature search …

… -governmental organisations will have … biological therapy in developing countries to treat
IBD, (3) the necessary infrastructure for selecting patients with IBD who need biological therapy…

… in IBD [Citation9], the following article will focus on the ‘top-down’ approach to biological
therapy … describes a traditional therapeutic approach, based on a step-wise intensification of CD …

… to treatment with biological agents because the relative efficacy of biological agents should
… whom standard therapies were unsuccessful with patients for whom biological agents were …

… to biologic therapy, but can be caused by the concomitant therapies in inflammatory bowel
disease (IBD… Pancreatitis in patients with IBD, who started on anti-TNF therapy in combination …

… We aimed to compile evidence from multiple meta-analyses examining the safety of
biological therapies used in ulcerative colitis into one accessible and usable document. …